SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present a company overview, discuss recent developments and review upcoming milestones at the medical device partnering conference: Investment-In-Innovation (IN3) SUMMIT on October 27th in San Francisco, CA at the Intercontinental Mark Hopkins Hotel. IN3 events bring together early/mid/late-stage, medical technology innovators with investors, venture capitalists, and business development executives.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
IN3 Summit is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. Leading venture capital firms and corporate acquirers are expected to attend to hear the latest innovations and investment opportunities.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
[email protected]
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
[email protected]
Jim Frakes
Chief Financial Officer
858.459.7800 x300
[email protected]
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
[email protected]
SOURCE Aethlon Medical, Inc.
Share this article